Synopsis
0
VMF
0
Australia
DRUG PRODUCT COMPOSITIONS0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
FDF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - INJECTABLE;INJECTION - EQ 1GM BASE/V...DOSAGE - INJECTABLE;INJECTION - EQ 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 50679
DOSAGE - INJECTABLE;INJECTION - EQ 2GM BASE/V...DOSAGE - INJECTABLE;INJECTION - EQ 2GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 50679
DOSAGE - INJECTABLE;INJECTION - EQ 500MG BASE...DOSAGE - INJECTABLE;INJECTION - EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 50679
Related Excipient Companies
Pfanstiehl
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kirsch Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Parenteral
Fillers, Diluents & Binders
Thickeners and Stabilizers
API Stability Enhancers
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
26
PharmaCompass offers a list of Cefepime Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Cefepime Hydrochloride manufacturer or Cefepime Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Cefepime Hydrochloride manufacturer or Cefepime Hydrochloride supplier.
PharmaCompass also assists you with knowing the Cefepime Hydrochloride API Price utilized in the formulation of products. Cefepime Hydrochloride API Price is not always fixed or binding as the Cefepime Hydrochloride Price is obtained through a variety of data sources. The Cefepime Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A HY-B0616 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of HY-B0616, including repackagers and relabelers. The FDA regulates HY-B0616 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. HY-B0616 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of HY-B0616 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A HY-B0616 supplier is an individual or a company that provides HY-B0616 active pharmaceutical ingredient (API) or HY-B0616 finished formulations upon request. The HY-B0616 suppliers may include HY-B0616 API manufacturers, exporters, distributors and traders.
click here to find a list of HY-B0616 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A HY-B0616 DMF (Drug Master File) is a document detailing the whole manufacturing process of HY-B0616 active pharmaceutical ingredient (API) in detail. Different forms of HY-B0616 DMFs exist exist since differing nations have different regulations, such as HY-B0616 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A HY-B0616 DMF submitted to regulatory agencies in the US is known as a USDMF. HY-B0616 USDMF includes data on HY-B0616's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The HY-B0616 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of HY-B0616 suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The HY-B0616 Drug Master File in Japan (HY-B0616 JDMF) empowers HY-B0616 API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the HY-B0616 JDMF during the approval evaluation for pharmaceutical products. At the time of HY-B0616 JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of HY-B0616 suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a HY-B0616 Drug Master File in Korea (HY-B0616 KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of HY-B0616. The MFDS reviews the HY-B0616 KDMF as part of the drug registration process and uses the information provided in the HY-B0616 KDMF to evaluate the safety and efficacy of the drug.
After submitting a HY-B0616 KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their HY-B0616 API can apply through the Korea Drug Master File (KDMF).
click here to find a list of HY-B0616 suppliers with KDMF on PharmaCompass.
A HY-B0616 CEP of the European Pharmacopoeia monograph is often referred to as a HY-B0616 Certificate of Suitability (COS). The purpose of a HY-B0616 CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of HY-B0616 EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of HY-B0616 to their clients by showing that a HY-B0616 CEP has been issued for it. The manufacturer submits a HY-B0616 CEP (COS) as part of the market authorization procedure, and it takes on the role of a HY-B0616 CEP holder for the record. Additionally, the data presented in the HY-B0616 CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the HY-B0616 DMF.
A HY-B0616 CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. HY-B0616 CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of HY-B0616 suppliers with CEP (COS) on PharmaCompass.
A HY-B0616 written confirmation (HY-B0616 WC) is an official document issued by a regulatory agency to a HY-B0616 manufacturer, verifying that the manufacturing facility of a HY-B0616 active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting HY-B0616 APIs or HY-B0616 finished pharmaceutical products to another nation, regulatory agencies frequently require a HY-B0616 WC (written confirmation) as part of the regulatory process.
click here to find a list of HY-B0616 suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing HY-B0616 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for HY-B0616 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture HY-B0616 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain HY-B0616 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a HY-B0616 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of HY-B0616 suppliers with NDC on PharmaCompass.
HY-B0616 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of HY-B0616 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right HY-B0616 GMP manufacturer or HY-B0616 GMP API supplier for your needs.
A HY-B0616 CoA (Certificate of Analysis) is a formal document that attests to HY-B0616's compliance with HY-B0616 specifications and serves as a tool for batch-level quality control.
HY-B0616 CoA mostly includes findings from lab analyses of a specific batch. For each HY-B0616 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
HY-B0616 may be tested according to a variety of international standards, such as European Pharmacopoeia (HY-B0616 EP), HY-B0616 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (HY-B0616 USP).
